Aligos Therapeutics, Inc. Common Stock
ALGSAligos Therapeutics, Inc. is a biotechnology company focused on developing therapies for liver diseases, viral infections, and related conditions. The company leverages novel approaches in drug discovery and development to address unmet medical needs, particularly targeting hepatitis B virus (HBV) and other chronic liver diseases.
Company News
Aligos Therapeutics presented positive Phase 1 follow-up data for pevifoscorvir sodium showing sustained reductions in HBV viral markers and cccDNA reservoir. The company reported that 40% of HBeAg+ participants achieved HBsAg levels below 3,000 IU/mL at week 48, potentially qualifying them for functional cure therapy. Preclinical data demonstrat...
Aligos Therapeutics has entered into an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pevifoscorvir sodium for chronic hepatitis B in Greater China. Aligos will receive a $25M upfront payment and up to $420M in milestone payments plus royalties, while retaining rights in the US, Europe, Japan, and South Kore...
Aligos Therapeutics reported significant progress in its Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B, completing enrollment of HBeAg- participants with interim analyses expected in 2026. The company also advanced ALG-170675, a dual-mechanism antisense oligonucleotide, into IND-enabling studies in partnership with Xiame...
Aligos Therapeutics announced positive clinical data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) in Denver. The company presented Phase 1 monotherapy data for pevifoscorvir sodium, a potential first-/best-in-class CAM-E for chronic hepatitis B virus infection, showing high viral suppression. Additi...
Aligos Therapeutics announced that its Compensation Committee granted non-qualified stock options to purchase 81,100 shares to newly hired employees on January 29, 2026, as an inducement for employment. The options have an exercise price equal to the closing stock price on the grant date and will vest over four years with 25% vesting on the first...
